Adhera Therapeutics, Inc.
ATRX0.00010.00% ( 0.0000 )
Adhera Therapeutics, Inc. (ATRX)
Adhera Therapeutics, Inc., a biotech company, focuses on the discovery, development, and commercialization of small molecule drugs. The company is developing ML...
- Open
- --
- High
- --
- Low
- --
- Prev. Close
- 0.0001
- Volume
- 0
- Turnover
- 0
- Avg Price
- --
- Bid/Ask Ratio
- --
- Amplitude
- --
- 52wk High
- 0.0100
- Volume Ratio
- 0.00
- Turnover Ratio
- --
News
- benzinga_article · May 7 at 11:05 AM
Why Is Phoenix Asia Stock Gaining Today?
- Tip Ranks · Apr 9 at 05:58 PM
Adheris Health Grants 60 Million Long-Dated Employee Options
- prnewswire · Apr 7 at 04:47 PM
17:46 ETALIT Investors Have Opportunity to Lead Alight, Inc. Securities Fraud Lawsuit
- MorningStar · Apr 6 at 06:57 AM
Affinia Therapeutics Receives Approval from Health Canada to Initiate the UPBEAT© Trial, a Phase 1/2 Clinical Trial to Investigate AFTX-201 as a Treatment for BAG3-Associated Dilated Cardiomyopathy (DCM)
- Unusual Whales · Jan 25 at 06:12 PM
Ascletis starts Phase II study with ASC30 in US for diabetes treatment. Expect data in Q3 2026. ASC30 shows up to 7.7% weight loss in 13-week study with overweight individuals.
- prnewswire · Jan 25 at 06:12 PM
19:10 ET Ascletis Announces First Participants Dosed in a 13-week U.S. Phase II Study with ASC30, an Oral Small Molecule GLP-1R Agonist for the Treatment of Diabetes
